Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice
Key Points
-
National Comprehensive Cancer Network (NCCN) Guidelines identify the most up-to-date treatment to help medical oncologists and community oncologists.
-
Sacituzumab govitecan is the only antibody-drug conjugate (ADC) with level 1 evidence for improved survival in advanced triple-negative breast cancer (TNBC).
-
ASCENT-04 data have implications for the ASCENT-05 trial and use of datopotamab deruxtecan in TNBC.
Community oncologists often treat more than one disease and therefore heavily rely on NCCN Guidelines when deciding which regimen is best for a patient.
Advanced or metastatic TNBC is aggressive and tends to grow quickly. The pivotal ASCENT-04/KEYNOTE-D19 clinical trial, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, provided level 1 evidence that sacituzumab govitecan, an ADC, improves survival for these patients.
Hope Rugo, MD, FASCO, City of Hope Comprehensive Cancer Center, and Arya Mariam Roy, MD, of The Ohio State University Comprehensive Cancer Center, reviewed the data presented at ASCO and explained how moving this regimen earlier into the treatment plan can help patients.
In addition, Dr. Rugo discussed the implications of the ASCENT-04 data for ASCENT-05, which is investigating sacituzumab govitecan in combination with pembrolizumab after surgery versus either pembrolizumab alone or pembrolizumab plus capecitabine in patients with early-stage TNBC. Moreover, she emphasized what the findings could mean for datopotamab deruxtecan, another ADC that targets the TROP-2 protein.